Affimed N.V. (AFMD)

Trade AFMD now with
2/13/2018 3:04:07 AM Affimed N.V. Announces Pricing Of Public Offering Of 11.5 Mln Shares At $2.00/shr
12/11/2017 5:04:08 AM Affimed Presents Data From Phase 1b Combination Study Of AFM13 With Pembrolizumab At ASH
11/7/2017 7:38:48 AM Affimed Q3 Net Loss EUR 8.1 Mln Or EUR 0.18 Per Share
11/1/2017 9:31:00 AM Affimed To Present Clinical And Preclinical Data On Immune Cell Engagers At ASH
8/1/2017 7:40:05 AM Affimed Posts Q2 Loss Per Share $0.18 Vs Loss $0.24 Last Year
6/27/2017 5:03:03 AM Affimed Reports Presentation Of Preclinical Data On AFM24 And AFM26 At EACR-AACR-SIC 2017
6/6/2017 5:02:04 AM Affimed Presents Data On First-in-Class BCMA-Targeting Immune Cell Engager AFM26 At ASCO Annual Meeting 2017
5/17/2017 7:33:13 AM Affimed N.V. Q1 Net Loss €7.8 Mln Or €0.19/shr Vs. Net Loss €8.5 Mln Or €0.25/shr Last Year
3/30/2017 7:33:58 AM Affimed Q4 Net Loss EUR 5.4 Mln Or EUR 0.16/shr Vs Loss Of EUR 6.3 Mln Or EUR 0.19/Shr Last Year
1/31/2017 5:07:05 AM AbCheck Reports Achievement Of First Clinical Milestone In Its Antibody Discovery Collaboration With Eli Lilly
1/20/2017 9:18:12 AM Affimed Prices Public Offering Of 10 Mln Of Its Common Shares At $1.80/Shr
1/19/2017 4:04:11 PM Affimed Announces Proposed Public Offering Of Common Stock
1/11/2017 8:54:31 AM Affimed Provides An Update On Its NK-cell Engager Platform
12/6/2016 5:04:55 AM Affimed Presents New Preclinical Data On Bi- And Trispecific Immune Cell Engagers At ASH
11/2/2016 7:36:10 AM Affimed Q3 Loss Per Share €0.31 Vs Loss €0.24 Last Year
10/4/2016 5:01:18 AM Affimed Presents Preclinical Data On Lead Candidate AFM13
8/10/2016 7:37:17 AM Affimed Q2 Loss Per Share €0.24 Vs Loss €0.19 Last Year